Spots Global Cancer Trial Database for breast tumors
Every month we try and update this database with for breast tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | NCT03911453 | Breast Cancer | Rucaparib | 21 Years - | University of Arizona | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | NCT03310957 | Triple Negative... | ladiratuzumab v... Pembrolizumab | 18 Years - | Seagen Inc. | |
| A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | NCT02296801 | Breast Cancer Breast Carcinom... Breast Tumors | Letrozole palbociclib | 18 Years - | NSABP Foundation Inc | |
| Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study | NCT02861859 | Breast Cancer | Olanzapine Olanzapine Plac... | 18 Years - | Ottawa Hospital Research Institute | |
| Delphinus SoftVue Prospective Case Collection - ARM 1 | NCT03257839 | Breast Neoplasm... | Routine Full-Fi... Routine Digital... Automated Whole... | 18 Years - | Delphinus Medical Technologies, Inc. | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | NCT00496860 | Progressive Met... | ALT-801 | 18 Years - | Altor BioScience | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery | NCT02496065 | Tumors, Breast | BLZ-100 | 18 Years - | Blaze Bioscience Inc. | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer | NCT01265927 | Breast Neoplasm... | GRN163L in comb... | 18 Years - | Indiana University | |
| Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant | NCT00639171 | Breast Tumors | 18 Years - 70 Years | State University of New York - Upstate Medical University | ||
| Delphinus SoftVue Prospective Case Collection - ARM 2 | NCT02977247 | Breast Neoplasm... | Non-Interventio... Automated Whole... | 18 Years - | Delphinus Medical Technologies, Inc. | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | NCT02632071 | Metastatic Brea... Breast Carcinom... | ACY-1215 Nab-paclitaxel | 18 Years - | Columbia University | |
| A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions | NCT00243698 | Breast Tumors | SonoVue (sulphu... | 18 Years - | University Hospital, Tours | |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | NCT01498588 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of the B... Neoplasms, Brea... Tumors, Breast | Eribulin Doxorubicin Cyclophosphamid... Pegfilgrastim | 18 Years - | Emory University | |
| Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine | NCT02004834 | Breast Tumors Hypotension Bradycardia | levobupivacaine | 18 Years - 80 Years | University Hospital Dubrava | |
| Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer | NCT00774878 | Breast Neoplasm... | AVE1642 Fulvestrant | 18 Years - | Sanofi | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| Clinical Study of 18F-FAPI-RGD in Breast Tumors | NCT05976620 | Breast Tumors | 18 Years - | Sichuan Provincial People's Hospital | ||
| Biomarker Study of Breast Tumors | NCT00941408 | Breast Tumors | Diagnostic tumo... | 18 Years - | National University Hospital, Singapore | |
| Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | NCT01218529 | Brain Metastase... Lung Tumors Breast Tumors | Lapatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment | NCT02891681 | Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Malignant Neopl... | Optical Tomogra... | 18 Years - | Washington University School of Medicine | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer | NCT03511378 | Breast Cancer | Lupin's Pegfilg... Neulasta® | 18 Years - | Lupin Ltd. | |
| Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | NCT01218529 | Brain Metastase... Lung Tumors Breast Tumors | Lapatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer | NCT01980823 | Breast Cancer Breast Tumors Cancer of Breas... | Metformin Atorvastatin Breast surgery | 21 Years - | Columbia University | |
| Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | NCT00921115 | Invasive Breast... | Fulvestrant Anastrazole | 18 Years - | University of Kansas Medical Center | |
| Simulated Screening Study for Breast Imaging | NCT01807754 | Breast Cysts Breast Tumors | X-ray and ultra... Photoacoustic i... | 30 Years - 80 Years | University of Michigan | |
| Therapeutic Dose Monitoring (TDM) of Tamoxifen | NCT05133674 | Breast Cancer Breast Carcinom... Breast Tumors Cancer of Breas... Malignant Neopl... | Tamoxifen 20 mg | 18 Years - | Karolinska University Hospital | |
| A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | NCT02296801 | Breast Cancer Breast Carcinom... Breast Tumors | Letrozole palbociclib | 18 Years - | NSABP Foundation Inc | |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | NCT02187991 | Breast Cancer Breast Carcinom... Breast Tumors Malignant Neopl... | Paclitaxel Alisertib | 18 Years - | US Oncology Research | |
| A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | NCT02296801 | Breast Cancer Breast Carcinom... Breast Tumors | Letrozole palbociclib | 18 Years - | NSABP Foundation Inc | |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | NCT00356681 | Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre... | AMG 706 placebo Bevacizumab AMG 706 Paclitaxel | 18 Years - | Amgen | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | NCT02225470 | HER2-Negative B... Triple Negative... Breast Cancer Cancer of Breas... Breast Tumors | E7389 (Eribulin... Vinorelbine inj... | 18 Years - 70 Years | Eisai Inc. | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer | NCT02632045 | Metastatic Brea... Breast Carcinom... | LEE-011 Fulvestrant Placebo | 18 Years - | Columbia University | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment | NCT02891681 | Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Malignant Neopl... | Optical Tomogra... | 18 Years - | Washington University School of Medicine | |
| Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis | NCT04132960 | Breast Tumors | DS-8201a | 18 Years - | UNICANCER | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions | NCT00243698 | Breast Tumors | SonoVue (sulphu... | 18 Years - | University Hospital, Tours | |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | NCT02225470 | HER2-Negative B... Triple Negative... Breast Cancer Cancer of Breas... Breast Tumors | E7389 (Eribulin... Vinorelbine inj... | 18 Years - 70 Years | Eisai Inc. | |
| Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | NCT02472353 | Breast Cancer Breast Tumors | Metformin Doxorubicin | 21 Years - | Avera McKennan Hospital & University Health Center | |
| Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study | NCT02861859 | Breast Cancer | Olanzapine Olanzapine Plac... | 18 Years - | Ottawa Hospital Research Institute | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | NCT01218529 | Brain Metastase... Lung Tumors Breast Tumors | Lapatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | NCT00356681 | Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre... | AMG 706 placebo Bevacizumab AMG 706 Paclitaxel | 18 Years - | Amgen | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
